Which medication class is a known potential cause of drug-induced thrombocytopenia and should be considered in evaluation?

Which medication class is a known potential cause of drug-induced thrombocytopenia and should be considered in evaluation?

• A. ACE inhibitors
• B. Statins
• C. Beta-blockers
• D. H2-antihistamines such as ranitidine

Answer: (D)

Drug-induced immune thrombocytopenia occurs when a medication triggers antibodies that bind to platelets only in the presence of that drug, leading to platelet destruction and a sudden drop in platelet count. Because this reaction is immune-mediated, the timeline often fits with starting a new medication and the severity can be abrupt. H2 antihistamines, such as ranitidine, are a known (though rare) potential cause of this condition. When a patient presents with new-onset thrombocytopenia and there’s a recent initiation of an H2 blocker, this class should be considered in the evaluation. Discontinuing the suspected agent often leads to a rapid rise in platelets over days, and clinically this supports the diagnosis. Re-exposure can reproduce the thrombocytopenia, so re-challenge is avoided. Other listed drugs aren’t classically linked to drug-induced thrombocytopenia as strongly. ACE inhibitors, statins, and beta-blockers can be associated with other adverse effects, but they are not typical culprits for immune-mediated platelet destruction in most cases, so they’re less likely explanations unless there are additional supporting clues.

Drug-induced immune thrombocytopenia occurs when a medication triggers antibodies that bind to platelets only in the presence of that drug, leading to platelet destruction and a sudden drop in platelet count. Because this reaction is immune-mediated, the timeline often fits with starting a new medication and the severity can be abrupt.

H2 antihistamines, such as ranitidine, are a known (though rare) potential cause of this condition. When a patient presents with new-onset thrombocytopenia and there’s a recent initiation of an H2 blocker, this class should be considered in the evaluation. Discontinuing the suspected agent often leads to a rapid rise in platelets over days, and clinically this supports the diagnosis. Re-exposure can reproduce the thrombocytopenia, so re-challenge is avoided.

Other listed drugs aren’t classically linked to drug-induced thrombocytopenia as strongly. ACE inhibitors, statins, and beta-blockers can be associated with other adverse effects, but they are not typical culprits for immune-mediated platelet destruction in most cases, so they’re less likely explanations unless there are additional supporting clues.